Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis

Science

Volumn 277, Issue 5332, 1997, Pages 1652-1655

  De Maria, Ruggero ^a   Lenti, Luisa ^b   Malisan, Florence ^a   D'Agostino, Federica ^b   Tomassini, Barbara ^a   Zeuner, Ann ^a   Rippo, Maria Rita ^a   Testi, Roberte ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CERAMIDE; CYSTEINE PROTEINASE; FAS ANTIGEN; GANGLIOSIDE; GANGLIOSIDE GD3; SYNTHETASE;

APOPTOSIS; ARTICLE; CELL MEMBRANE POTENTIAL; CONTROLLED STUDY; ENZYME ACTIVATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LIPOGENESIS; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION;

ANTIGENS, CD95; APOPTOSIS; CERAMIDES; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; ENZYME INHIBITORS; GANGLIOSIDES; GOLGI APPARATUS; HUMANS; MEMBRANE POTENTIALS; MITOCHONDRIA; MORPHOLINES; OLIGONUCLEOTIDES, ANTISENSE; SIALYLTRANSFERASES; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0030863670     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.277.5332.1652     Document Type: Article

References (37)

1. S. Nagata and P. Golstein, Science 267, 1449 (1995); P. H. Krammer et al., Immunol. Rev. 142, 175 (1994).
2. S. Nagata and P. Golstein, Science 267, 1449 (1995); P. H. Krammer et al., Immunol. Rev. 142, 175 (1994).
3. M. Muzio et al., Cell 85, 817 (1996); M. P. Boldin, T. M. Goncharov, Y. V. Goltsev, D. Wallach, ibid., p. 803.
4. M. Muzio et al., Cell 85, 817 (1996); M. P. Boldin, T. M. Goncharov, Y. V. Goltsev, D. Wallach, ibid., p. 803.
5. M. Los et al, Nature 375, 81 (1995); M. Enari, H. Hug, S. Nagata, ibid., p. 78.
6. M. Los et al, Nature 375, 81 (1995); M. Enari, H. Hug, S. Nagata, ibid., p. 78.
7. R. Testi, Trends Biochem. Sci. 21, 468 (1996).
8. M. G. Cifone et al., J. Exp. Med. 180, 1547 (1994); M. G. Cifone et al., EMBO J. 14, 5859 (1995); R. De Maria et al., J. Clin. Invest 97, 316 (1996).
9. M. G. Cifone et al., J. Exp. Med. 180, 1547 (1994); M. G. Cifone et al., EMBO J. 14, 5859 (1995); R. De Maria et al., J. Clin. Invest 97, 316 (1996).
10. M. G. Cifone et al., J. Exp. Med. 180, 1547 (1994); M. G. Cifone et al., EMBO J. 14, 5859 (1995); R. De Maria et al., J. Clin. Invest 97, 316 (1996).
11. Y. A. Hannun and L. M. Obeid, Trends Biochem. Sci. 20, 73 (1995); L. M. Obeid, C. M. Linardic, L. A. Karolak, Y. A. Hannun, Science 259, 1769 (1993); S. Mathias and R. Kolesnick, Adv. Lipid Res. 25, 65 (1993); R. Kolesnick and Z. Fuks, J. Exp. Med. 181, 1949 (1995).
12. Y. A. Hannun and L. M. Obeid, Trends Biochem. Sci. 20, 73 (1995); L. M. Obeid, C. M. Linardic, L. A. Karolak, Y. A. Hannun, Science 259, 1769 (1993); S. Mathias and R. Kolesnick, Adv. Lipid Res. 25, 65 (1993); R. Kolesnick and Z. Fuks, J. Exp. Med. 181, 1949 (1995).
13. Y. A. Hannun and L. M. Obeid, Trends Biochem. Sci. 20, 73 (1995); L. M. Obeid, C. M. Linardic, L. A. Karolak, Y. A. Hannun, Science 259, 1769 (1993); S. Mathias and R. Kolesnick, Adv. Lipid Res. 25, 65 (1993); R. Kolesnick and Z. Fuks, J. Exp. Med. 181, 1949 (1995).
14. Y. A. Hannun and L. M. Obeid, Trends Biochem. Sci. 20, 73 (1995); L. M. Obeid, C. M. Linardic, L. A. Karolak, Y. A. Hannun, Science 259, 1769 (1993); S. Mathias and R. Kolesnick, Adv. Lipid Res. 25, 65 (1993); R. Kolesnick and Z. Fuks, J. Exp. Med. 181, 1949 (1995).
15. P. Santana et al., Cell 86, 189 (1996).
16. D. Allan and K.-J. Kallen, Progr. Lipid Res. 32, 195 (1993); G. van Echten and K. Sandhoff, J. Biol. Chem. 268, 5341 (1993).
17. D. Allan and K.-J. Kallen, Progr. Lipid Res. 32, 195 (1993); G. van Echten and K. Sandhoff, J. Biol. Chem. 268, 5341 (1993).
18. I. Cascino, G. Papoff, R. De Maria, R. Testi, G. Ruberti, J. Immunol. 156, 13 (1996).
19. R. De Maria et al., unpublished results.
20. 3), and revealed by immunoperoxidase staining. For fluorescent ganglioside studies, cells were incubated for 30 min at 37°C with pyrene-labeled GM3, then stimulated. Gangliosides were then extraded and chromatographed on HPTLC plates. Pyrene-conjugated gangliosides were visualized with an ultraviolet (UV) lamp at 254 nm.
21. Cell viability was evaluated by ethidium bromide-acridine orange staining and fluorescence microscopy. Hypodiploid nuclei were evaluated by hypotonic propidium iodide solution staining and flow cytometric analysis, with the use ot a FACScan (Becton Dickinson; San Jose, CA). Internucleosomal DNA fragmentation was analyzed by DNA electrophoresis.
22. K. Sasaki et al., J. Biol. Chem. 269, 15950 (1994); K. Nara et al., Proc. Natl. Acad. Sci. U.S.A. 91, 7952 (1994); M. Haraguchi et al., ibid., p. 10455.
23. K. Sasaki et al., J. Biol. Chem. 269, 15950 (1994); K. Nara et al., Proc. Natl. Acad. Sci. U.S.A. 91, 7952 (1994); M. Haraguchi et al., ibid., p. 10455.
24. K. Sasaki et al., J. Biol. Chem. 269, 15950 (1994); K. Nara et al., Proc. Natl. Acad. Sci. U.S.A. 91, 7952 (1994); M. Haraguchi et al., ibid., p. 10455.
25. The GD3 synthase cDNA was cloned in the PUC vector, and a 1152-base pair (bp) Apa I fragment was further cloned in the pEGFP-C3 expression vector (Clontek; Palo Alto, CA). The ΔBH deletion mutant was generated by removing the COOH-terminal portion of the enzyme with Bam HI. The 514-bp Bam HI-Apa I fragment was then cloned in pEGFP-C3. HuT78 cells were electroporated (Gene Pulser, Bio-Rad; Hercules, CA), and viable cells were recovered by lymphoprep density gradient centrifugation. After 24 hours of culture, cells were analyzed by fluorescence microscopy. Transfection efficiency was typically 20 to 25% as measured by fluorescence emission.
26. Coupled transcription and translation of PARP, cloned into the pGEM plasmid under the T7 promoter, was performed with the TNT kit (Promega, Madison, WI). Each reaction was carried out for 2 hours at 37°C, then samples were resolved by 10% SDS-polyacrylamide gel electrophoresis and autoradiographed. Caspase inhibitors Ac-YVAD-CMK (Ac-Tyr-Val-Ala-Asp-chlorometylketone), Ac-DEVD-CHO (Ac-Asp-Glu-Val-Asp-CHO), and ZVAD-FMK (N-benzyloxycarbonyl-Val-Ala-Asp-fluorometyl-ketone) were from Bachern (Bubendorf, Switzerland).
27. G. Kroemer, N. Zamzami, S. A. Susin, Immunol. Today 18, 44 (1997).
28. m were therefore evaluated by the shift in fluorescence emission.
29. m were therefore evaluated by the shift in fluorescence emission.
30. N. S. Radin, J. A. Shayman, J.-I. Inokuchi, Adv. Lipid Res. 26, 183 (1993); N. S. Radin and R. R. Vunnan, Methods Enzymol. 72, 673 (1981).
31. N. S. Radin, J. A. Shayman, J.-I. Inokuchi, Adv. Lipid Res. 26, 183 (1993); N. S. Radin and R. R. Vunnan, Methods Enzymol. 72, 673 (1981).
32. G. Zeng, T. Ariga, X.-b. Gu, R. K. Yu, Proc. Natl. Acad. Sci. U.S.A. 92, 8670 (1995).
33. PDMP was from Matreya (Pleasant Gap, PA). The GD3 synthase antisense oligodeoxynucleotide sequence (5′-CAGTACAGCCATGGCCCCTCT-3′) was selected on the 5′ region of the gene surrounding the second initiator ATG. A scrambled sequence from the same deoxynucleotides (5′-CGACCTACCTATGCGCTACCG-3′) was also used as a control. To increase nuclease resistence, both oligodeoxynucleotide sequences were phosphorothioatemodified on every second deoxynucleotide.
34. G. R. Matyas and D. J. Morré, Biochim. Biophys. Acta, 921, 599 (1987).
35. P. Sarti et al., Biochem. J. 267, 413 (1990); G. Tettamanti and L. Riboni, Prog. Brain Res. 101, 77 (1994).
36. P. Sarti et al., Biochem. J. 267, 413 (1990); G. Tettamanti and L. Riboni, Prog. Brain Res. 101, 77 (1994).
37. We thank T. Nishi (Tokyo Research Laboratories, Japan); L. J. Old (Ludwig Institute, New York); R. Beyaert (University of Ghent, Belgium) for kindly providing reagents; and V. Zacchei for expert assistance. Supported by grants to R.T. from Associazione Italiana Ricerca sul Cancro (AIRC), Consiglio Nazionale delle Ricerche (CNR), Ministero dell'Universitá e della Ricerca Scientifica e Tecnologica (MURST), and the European Community Biomed 2 and Human Caprtal and Mobility Programs. R.D.M. is an AIRC fellowship holder.